An overview of Novel Drug Delivery Systems for Acne


  • Neha Singh Amity Institute of Pharmacy, Amity University, Lucknow Campus, Lucknow-226028, India
  • Mahesh Singh Amity Institute of Pharmacy, Amity University, Lucknow Campus, Lucknow-226028, India
  • Surbhi Panwar Amity Institute of Pharmacy, Amity University, Lucknow Campus, Lucknow-226028, India



Acne, Antibiotics, Drug Delivery System, Liposomes, Microsphere, Oral contraceptives


Acne vulgaris is a type of chronic disease of the skin which is mainly caused by the blockage in the sebaceous gland or having any inflammation in those glands which is together is known as pilosebaceous units. It mainly affects the areas having the highest number of sebaceous follicles; those are the face, the back and upper region of the chest. It is a disease that mainly affects the adolescent age group but can be found in any age group. These are present as inflammatory pustules, papules, cysts and nodules, non-inflammatory closed comedones (whiteheads), ripen comedones (blackheads), or a mixture of lesions. Acne is most commonly seen in almost every human being at some point in their lives. There are 20-25 chances of progression of acne to the severe case which leads to permanent scarring. These complications lead to psychological problems like depression, social isolation, lowered self-esteem, and lowered self-confidence. The aim of treating acne is to prevent severe and long-term complications. The present review focuses on novel drug delivery systems for the treatment of acne. It also includes conventional treatments currently available in the market, its limitation and different strategies to overcome these limitations.


Download data is not yet available.


Vyas A, Kumar Sonker A, Gidwani B. Carrier-based drug delivery system for treatment of acne. The scientific world journals. 2014;2014.

Enshaieh S, Jooya A, Siadat AH, Iraji F. The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: a randomized, double-blind placebo-controlled study. Indian Journal of Dermatology, Venereology, and Leprology. 2007 Jan 1;73(1):22.

Lin H, Xie Q, Huang X, Ban J, Wang B, Wei X, Chen Y, Lu Z. Increased skin permeation efficiency of imperatorin via charged ultradeformable lipid vesicles for transdermal delivery. International journal of nanomedicine. 2018; 13:831.

Abdel-Messih HA, Ishak RA, Geneidi AS, Mansour S. Tailoring novel soft Nano-vesicles ‘Flexosomes’ for enhanced transdermal drug delivery: Optimization, characterization and comprehensive ex vivo–in vivo evaluation. International journal of pharmaceutics. 2019 Apr 5; 560:101-15.

Tadwee IK, Gore S, Giradkar P. Advances in topical drug delivery system: a review. Int. J. of Pharm. Res. & All. Sci. 2012;1(1):14-23.

Alomrani AH, Badran MM. Flexosomes for transdermal delivery of meloxicam: characterization and antiinflammatory activity. Artificial cells, nanomedicine, and biotechnology. 2017 Feb 17;45(2):305-12.

El-Nabarawi MA, Shamma RN, Farouk F, Nasralla SM. Dapsone-Loaded Invasomes as a Potential Treatment of Acne: Preparation, Characterization, and In Vivo Skin Deposition Assay. AAPS PharmSciTech. 2018 Jul 1;19(5):2174-84.

Jang YH, Lee KC, Lee SJ, Kim DW, Lee WJ. HR-1 Mice: A new inflammatory acne mouse model. Annals of dermatology. 2015 Jun 1;27(3):257-64.

Vats A, Sharma P. Formulation and evaluation of topical anti acne formulation of coriander oil. International Journal of Pharmacy and Pharmaceutical Science Research. 2012;2(3):61-6

Ascenso A, Salgado A, Euletério C, Praça FG, Bentley MV, Marques HC, Oliveira H, Santos C, Simões S. In vitro and in vivo topical delivery studies of tretinoin-loaded ultradeformable vesicles. European Journal of Pharmaceutics and Biopharmaceutics. 2014 Sep 1;88(1):48-55.

Fitz-Gibbon S, Tomida S, Chiu BH, Nguyen L, Du C, Liu M, Elashoff D, Erfe MC, Loncaric A, Kim J, Modlin RL. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. Journal of Investigative Dermatology. 2013 Sep 1;133(9):2152-60.

Jain AK, Jain A, Garg NK, Agarwal A, Jain A, Jain SA, Tyagi RK, Jain RK, Agrawal H, Agrawal GP. Adapalene loaded solid lipid nanoparticles gel: an effective approach for acne treatment. Colloids and Surfaces B: Biointerfaces. 2014 Sep 1; 121:222-9.

Dash M, Chiellini F, Ottenbrite RM, Chiellini E. Chitosan—A versatile semi-synthetic polymer in biomedical applications. Progress in polymer science. 2011 Aug 1;36(8):981-1014.

Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European journal of pharmaceutics and biopharmaceutics. 2000 Jul 3;50(1):161-77.

Chen H, Chang X, Weng T, Zhao X, Gao Z, Yang Y, Xu H, Yang X. A study of microemulsion systems for transdermal delivery of triptolide. Journal of controlled release. 2004 Aug 27;98(3):427-36.

Amselem S, Friedman D, inventors; Pharmos Corp, assignee. Solid fat nanoemulsions as drug delivery vehicles. United States patent US 5,576,016. 1996 Nov 19.

Akbarzadeh A, Rogaie-Rezaei Sadabady, Davaran S, Joo Woo S, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Kazem Nejati-Koshki. Liposome: classification, preparation, and applications. Nanoscale Research Lett. 2013; 8(1): 102. doi: 10.1186/1556-276X-8-102.

Kazi Masud K, Mandal Sattwa A, Biswas N, Guha A, Chatterjee S, Behera M, Kuotsu K. Niosomes: A future of targeted drug delivery systems. Journal of Advanced Pharmaceutical Technology and Research. 2010 Oct-Dec; 1(4): 374-380. doi: 10.4103/0110-5558.76435.

Kaity S, Maiti S, Ghosh AK, Pal D, Ghosh A, Banerjee S. Microsponges: A novel strategy for drug delivery system. Journal of Advanced Pharmaceutical Technology and Research. 2010 Jul-Sep; 1(3): 283-290. doi: 10.4103/0110-5558.72416.

Malhotra M, Jain NK, Niosomes as drug carriers. Indian Drugs. 1994; 31:81-6.

Udupa N. Niosomes as drug carriers. In: Jain NK, editor. Controlled and novel drug delivery. 1st edition. New Delhi: CBS Publishers and Distributors; 2002.

Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of Niosomes-Non-ionic surfactant vesicles. J Pharm Pharmacol. 1985; 37:863-8.

Brewer JM, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology. 1992; 75:570-5.

Moser P, Marchand-Arvier M, Labrude P, Handjani-Vila RM, Vignerson C. Haemoglobin niosomes. I. Preparation, functional and physic-chemical properties, and stability. Pharma Acta Helv. 1989; 64:192-202.

Moser P, Arvier MM, Labrude P, Vignerson C. Niosomes of haemoglobin. II. Vitrointeractions with plasma proteins and phagocytes. Pharm Acta Helv. 1990; 65:82-92.

Hu C, Rhodes DG. Proniosomes: A Novel Drug Carrier Preparation. Int J Pharm. 1999; 185:23-35.

Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vesicular systems (Niosomes and Liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol. 1988; 40:161-5.

Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. DDT. 2003; 8:24.

Gazibon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J control Release. 1998; 53:275-279. doi 10.1016/S0168-3659(97)00261-7.

Allen TM. Liposome. Opportunities in drug delivery. Drugs. 1997;54(Suppl 4):8-14.

Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta. 2007:1768:1121-1127 doi. 10.1016/l.bbamen.2007.01.019.

Hofheinz RD, Gnad Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs. 2005; 16:691-707. doi: 10.1097/01.cad.0000167902.53039.5a.

Nacht S, Kantz M. The microsponge; A novel topical programmable delivery system. Top Drug Deliv Syst. 1992; 42:299-325.

Badawi AA, Nour SA, Sakran WS, El-Mancy SMS. Preparation and Evaluation of Microemulsion Systems Containing Salicylic Acid. AAPS PharmSciTech. 2009 Dec; 10(4): 1081-1084. doi: 10.1208/s12249-009-9301-7.

Collier K, Matalonis S, Owen AJ. Evaluation of permeability enhancement by microemulsion in a caco-2 cell system. Proc Int Symp Control Release Bioact Mater. 1999; 26:5444.

Alany RG, Rades T, Agatonovic-Kustrin S, Dvies NM, Tucker IG. Effects of alcohols and diols on the phase behavior of quaternary systems. Int J Pharm. 2000; 196:141–145. doi: 10.1016/S0378-5173(99)00408-1.

Trotta M, Pattarino F, Grosa G. Formation of lecithin-based microemulsions containing n-alkanol phosphocholines. Int J Pharm.1998; 174:253–259. doi: 10.1016/S0378-5173(98)00273-7.

Marti-Mestres G, Nielloud F. Emulsions in health care applications—an overview. J Dispers Sci Technol. 2002; 23:419–439.

Osborne DW, Ward AJ, O’Neill KJ. Microemulsions as topical drug delivery vehicles: in-vitro transdermal studies of a model hydrophilic drug. J Pharm Pharmacol Comm. 1991; 43:451–454.

Jachowicz J, Berthiaume MD. Microemulsions vs. macroemulsions in hair care products. Cosmet Toiletries. 1993; 108:65–72.

Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015 Apr; 5(2): 123-127. doi: 10.1007/s13205-014-0214-0.

Hossain KMZ, Patel U, Ahmed I. Development of microspheres for biomedical applications: a review. Prog Biomater. 2015 Mar: 4:1-19. doi: 10.1007/s40204-014-0033-8.

Scheffel U, Rhodes BA, Natajaran TK, Wagner HN. Albumin microspheres for study of the reticuloendothelial system. J Nucl Med.1970; 13:498–503.

Jumaa M, Muller BW. Lipid emulsions as a novel system to reduce the haemolytic activity of lytic agents: Mechanism of protective effect. Eur J Pharm Sci. 2000; 9:285–90.

Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm. 1993;89: R9–R12.

Mukherjee S, Ray S, Thakur RS. Solid Lipid Nanoparticles: A modern Formulation Approach in Drug Delivery system. Indian J Pharm Sci. 2009 Jul-Aug; 71(4): 349-358. doi: 10.4103/0250-474X.57282.

Wichterle O, Lím D. Hydrophilic gels for biological use. Nature. 1960;185:117–118.

Kope?ek J, Yang J. Hydrogels as smart materials. Polym Int. 2007.

Kope?ek J. Hydrogels Biomaterials: A smart future? Biomaterials. Author manuscript; available in PMC 2008 Dec 1. doi: 10.1016/j.biomaterials.2007.07.044.

Liao DC. “Management of acne,” Journal of Family Practice, vol. 52, no. 1, pp. 43–51, 2003.

Leydon J. “Comparing facial tolerability of a 3-step acne system containing a novel solubilized 5% benzoyl peroxide lotion for normal to dry skin with that of a benzoyl peroxide/clindamycin combination prescription product,” Journal of the American Academy of Dermatology, vol. 58, supplement 2, no. 2, p. 15,2008.

Thiboutot D. Jarratt M. Rich P. Rist T. Rodriguez D. and Levy S. “A randomized, parallel, vehicle-controlled comparison of two erythromycin/benzoyl peroxide preparations for Acne vulgaris,” Clinical Therapeutics, vol. 24, no. 5, pp. 773–785, 2002.

Wang F. Kwak HS. Elbuluk N. et al., “Retinoic acid 4- hydroxylase inducibility and clinical response to isotretinoin in patients with acne,” Journal of the American Academy of Dermatology, vol. 61, no. 2, pp. 252–258, 2009.

Gabriels M. Brisaert M. and Plaizier-Vercammen J. “Densitometricthin layer chromatographic analysis of tretinoin and erythromycin in lotions for topical use in acne treatment,” European Journal of Pharmaceutics and Biopharmaceutics, vol.48, no. 1, pp. 53–58, 1999.

Spellman MC and Pincus SH. “Efficacy and safety of azelaic acid and glycolic acid combination therapy compared with tretinoin therapy for acne,” Clinical Therapeutics, vol. 20, no. 4, pp. 711–721, 1998.

Verschoore M, Poncet M. Czernielewski J. Sorba V. and Clucas A, “Adapalene 0.1% gel has low skin-irritation potential,” Journal of the American Academy of Dermatology, vol. 36, no. 6, supplement, pp. S104–S109, 1997.

Shalita AR. Berson DS. Thiboutot DM et al., “Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials,” Clinical Therapeutics, vol. 26, no. 11, pp. 1865–1873, 2004.

Xu Y. Yang X. and Xu X, “Preparation and evaluation of tea tree oil liposome,” West China Journal of Pharmaceutical Sciences, 2006.

Rougier A and Richard A, “Efficacy and safety of a new salicylic acid derivative as a complement of vitamin A acid in acne treatment,” European Journal of Dermatology, vol. 12, no. 4, pp.49–50, 2002.

Yaroshinsky A and Leyden J. “The safety and efficacy of clindamycin [1% as clindamycin phosphate and tretinoin (0.025%)] for the treatment of acne vulgaris: a combined analysis of results from six controlled safety and efficacy trials,” European Journal of Dermatology, vol. 50, no. 3, p. 23, 2004.

Vermeulen B. Remon JP. and Nelis H. “The formulation and stability of erythromycin-benzoyl peroxide in a topical gel,” International Journal of Pharmaceutics, vol. 178, no. 1, pp. 137–141, 1999.

Lucky AW. Maloney JM. Roberts J et al., “Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term treatment,” Journal of Drugs in Dermatology, vol. 6, no. 10, pp.981–987, 2007.

del Rosso JQ. “The use of sodium sulfacetamide 10%-sulfur5% emollient foam in the treatment of acne vulgaris,” Journal of Clinical and Aesthetic Dermatology, vol. 2, no. 8, pp. 26–29,2009.

How to cite this article:

Singh N, Singh M and Panwar S. An overview on Novel Drug Delivery Systems for Acne. Int. J. Res. Dev. Pharm. L. Sci. 2019; 8(4): 1-12. doi: 10.13040/IJRDPL.2278-0238.8(4).1-12

This Journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.



How to Cite

Singh, N. ., Singh , M. ., & Panwar , S. . (2019). An overview of Novel Drug Delivery Systems for Acne. International Journal of Research and Development in Pharmacy & Life Sciences, 8(4), 01-12.